Nasdaq from Stockholm Registration Committee announced today that it considers SynAct Pharma AB (“SynAct” or the “Company”) satisfies the applicable listing requirements and that it will approve the application for admission to trading of the Company’s shares on the Nasdaq Stockholm Main Market subject to compliance with customary conditions, including including the approval and registration of a prospectus by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and compliance with the requirement to distribute Company shares. The first day of trading on Nasdaq Stockholm is expected to be Tuesday, July 12, 2022and the last day of trading on Stock market should be Monday, July 11, 2022.
The first day of trading on Nasdaq Stockholm is expected to be July 12, 2022. Due to listing, SynAct will be removed from the list Stock market and the last trading day on Stock market should be July 11, 2022. SynAct shareholders will have no action to take in connection with admission to trading on Nasdaq Stockholm.
The listing of the Company’s shares on Nasdaq Stockholm is an important step in SynAct’s continued development and gives the Company additional access to the Swedish and international capital markets. SynAct is listed on Stock market since 2016, but the Board of Directors believes that the listing of the Company’s stock on Nasdaq Stockholm will increase the conditions for expanding SynAct’s shareholding and give the Company access to additional international and institutional investors , which is supposed to favor the continued development of the Company. In addition, the list also carries a seal of approval for SynAct and its operations.
“The fact that we have now been approved to list on the main list of Nasdaq Stockholm represents an important milestone for SynAct and our existing and new shareholders,” said Jeppe Øvlesen, CEO.
About List Change
The SynAct share will be traded on the Small Cap segment and will retain both its ticker (SYNACT) and its ISIN code (SE0008241491). As part of the change of list, there will be no offer or issue of new shares.
SynAct is preparing a prospectus in connection with the admission to trading of the shares on the Nasdaq Stockholm Main Market. The prospectus should be approved and registered by the Swedish Financial Supervisory Authority and published on the SynAct website, www.synactpharma.com, around July 8, 2022.
Setterwalls Advokatbyrå AB is acting as legal counsel to SynAct in connection with the listing.
The English text is an unofficial translation of the original Swedish text. In case of discrepancy between the Swedish text and the English translation, the Swedish text will prevail.
The information has been submitted, through the contact person below, for publication at 3:30 p.m. It’s the June 28, 2022.
For more information on SynAct Pharma ABplease contact:
CEO, SynAct Pharma AB
Telephone: +45 28 44 75 67
Email: [email protected]
CFO, SynAct Pharma AB
Telephone: +46 707 47 97 68
Email: [email protected]
About SynAct Pharma AB
SynAct Pharma AB conducts research and development activities in inflammatory diseases. The Company has a technology platform based on a novel class of drug candidates for acute deterioration of chronic inflammatory diseases with the primary goal of stimulating natural healing mechanisms. For more information: www.synactpharma.com.
(c) Decision 2022. All rights reserved., sources Press Releases – English